Status:
RECRUITING
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
Lead Sponsor:
Charles University, Czech Republic
Conditions:
VAP - Ventilator Associated Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
HyPerMICROBE is a single-centre, controlled, randomised, prospective, superiority clinical trial to compare the efficacy of daily oral care with 3% hydrogen peroxide (Oroxid®) versus standard of care ...
Detailed Description
Rationale: Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection (HAI) in the intensive care unit (ICU), and its impact is very high in terms of morbidity, length of hos...
Eligibility Criteria
Inclusion
- Age ≥18 years
- In-patient of ICU and expected to stay \> 5 days
- Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation (MV) ≥ 72h
- Clinical Pulmonary Infection score (CPIS) less than 6 at the baseline
- No history and symptoms of aspiration at the baseline
Exclusion
- ATB therapy of respiratory infection on admission
- Suspected pulmonary infection on admission and in the first 48h of mechanical ventilation
- Pregnancy
- Oral ulcers or injuries
- Patient with a history of hydrogen peroxide allergy
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06045429
Start Date
May 1 2024
End Date
December 1 2025
Last Update
July 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
3rd Faculty of Medicine and FNKV
Prague, Czechia, 11000